ME02506B - VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA - Google Patents

VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA

Info

Publication number
ME02506B
ME02506B MEP-2016-217A MEP21716A ME02506B ME 02506 B ME02506 B ME 02506B ME P21716 A MEP21716 A ME P21716A ME 02506 B ME02506 B ME 02506B
Authority
ME
Montenegro
Prior art keywords
formulation
formula
liquid aqueous
tnf
alpha
Prior art date
Application number
MEP-2016-217A
Other languages
German (de)
English (en)
French (fr)
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46051586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02506(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Publication of ME02506B publication Critical patent/ME02506B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (7)

1. Tečna vodena formula koja se uglavnom sastoji od:(1) 100 mg/ml adalimumaba; (2) 1 mg/ml polisorbata-80;(3)42 mg/ml manitola; i(4)vode, gdje formula ne sadrži pufer.
2. Tečna vodena formula zahtjeva 1, gdje se formula sas toji od: (1)100 mg/ml adalimumaba; (2)1 mg/ml polisorbata-80; (3) 42 mg/ml manitola; i (4) vode.
3. Tečna vodena formula zahtjeva 1 ili 2, gdje je formula stabilna do oko 30°C najmanje 6 dana.
4. Tečna vodena formula bilo kojeg od zahtjeva od 1 do 3, gdje je formula stabilna do oko 30°C najmanje 10 dana.
5. Tečna vodena formula bilo kojeg od zahtjeva od 1 do 4 koja ima osobinu odabranu iz grupe koja se sastoji od: a) provodljivosti manje od oko 2 mS/cm; b)Hidrodinamičkog promjera (Dh) koji je najmanje oko 50% manji od Dh proteina u pufer rastvoru u datoj koncentraciji; i c)Hidrodinamičkog promjera (Dh) manjeg od oko 4 nm.
6. Prethodno napunjen špric ili uređaj za samoubrizgavanje, koji se sastoji od formule bilo kojeg od zahtjeva od 1 do 5.
7. Formula bilo kojeg od zahtjeva 1-5 za upotrebu u liječenju reumatoidnog artritisa, Kronove bolesti, psorijaznog artritisa, psorijaze, juvenilnog idiopatskog artritisa, ankilozantnog spondilitisa, ulcerativnog kolitisa, ili hidradenitis suppurativa. 1
MEP-2016-217A 2010-11-11 2011-11-11 VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA ME02506B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41272810P 2010-11-11 2010-11-11
US41396010P 2010-11-15 2010-11-15
EP11839071.5A EP2637690B1 (en) 2010-11-11 2011-11-11 HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
PCT/US2011/060388 WO2012065072A2 (en) 2010-11-11 2011-11-11 IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS

Publications (1)

Publication Number Publication Date
ME02506B true ME02506B (me) 2017-02-20

Family

ID=46051586

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-217A ME02506B (me) 2010-11-11 2011-11-11 VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA

Country Status (28)

Country Link
US (5) US8821865B2 (me)
EP (1) EP2637690B1 (me)
JP (3) JP5919606B2 (me)
KR (1) KR101841527B1 (me)
CN (2) CN103458926B (me)
AU (2) AU2011325974B2 (me)
BR (1) BR112013011699B1 (me)
CA (1) CA2815689C (me)
CY (1) CY1118373T1 (me)
DK (1) DK2637690T3 (me)
ES (1) ES2601202T3 (me)
HR (1) HRP20161753T1 (me)
HU (1) HUE029457T2 (me)
IL (1) IL226217A (me)
LT (1) LT2637690T (me)
ME (1) ME02506B (me)
MX (1) MX344727B (me)
NZ (1) NZ609469A (me)
PL (1) PL2637690T3 (me)
PT (1) PT2637690T (me)
RS (1) RS55385B1 (me)
RU (2) RU2639386C2 (me)
SG (2) SG190069A1 (me)
SI (1) SI2637690T1 (me)
SM (1) SMT201600443B (me)
TW (2) TWI603739B (me)
WO (1) WO2012065072A2 (me)
ZA (1) ZA201406542B (me)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR20150055116A (ko) 2005-05-16 2015-05-20 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
WO2007038686A2 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
JP5656853B2 (ja) 2008-10-27 2015-01-21 ジェナリーテ， インコーポレイテッド 光学的な探査及び検知に基づくバイオセンサ
JP5919606B2 (ja) * 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2863951A1 (en) * 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
JP2015528001A (ja) 2012-07-11 2015-09-24 ティッシュテック，インク． Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201501715QA (en) 2012-09-07 2015-05-28 Coherus Biosciences Inc Stable aqueous formulations of adalimumab
ES2806946T3 (es) * 2012-10-26 2021-02-19 Lupin Atlantis Holdings Sa Composición farmacéutica estable de la proteína de fusión TNFR:Fc etanercept
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
JP2016505633A (ja) 2013-01-24 2016-02-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ＴＮＦα抗原結合性タンパク質
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
CA2926384A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
SG11201507365VA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
BR112016000563A2 (pt) 2013-07-19 2017-09-05 Hexal Ag Método de preparar uma formulação farmacêutica, método de usar ácido hexanóico e/ou ácido cítrico ou pelo menos um sal dos mesmos, formulação farmacêutica e método de modular ou determinar respostas imunes relacionadas à administração de uma formulação farmacêutica
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10688187B2 (en) * 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
LT2946765T (lt) * 2014-05-23 2016-11-25 Ares Trading S.A. Skysta farmacinė kompozicija
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
AU2015283270B9 (en) * 2014-06-30 2021-04-01 Merck Patent Gmbh Anti-TNFa antibodies with pH-dependent antigen binding
KR102500075B1 (ko) * 2014-10-08 2023-02-16 아지노모토 가부시키가이샤 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치
TW201628649A (zh) * 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
EP3297645A4 (en) 2015-05-20 2018-12-12 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
CA2994043A1 (en) * 2015-07-31 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Antibody variants
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2017136433A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR20250044934A (ko) 2016-10-19 2025-04-01 인벤라 인코포레이티드 항체 구조물
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
BR112019006689A2 (pt) 2016-10-25 2019-06-25 Regeneron Pharma métodos e sistemas para análise de dados de cromatografia
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
EP3559039A1 (en) 2016-12-22 2019-10-30 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
RU2665966C2 (ru) * 2016-12-30 2018-09-05 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
KR20180106974A (ko) * 2017-03-16 2018-10-01 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
US12042538B2 (en) 2017-09-19 2024-07-23 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
CN111491664A (zh) * 2017-09-20 2020-08-04 阿尔沃科技Hf公司 阿达木单抗的药物制剂
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US20210231651A1 (en) * 2018-04-30 2021-07-29 Genalyte, Inc. Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics
CN120795120A (zh) 2018-06-05 2025-10-17 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
CN112739378B (zh) * 2018-09-14 2025-05-06 田边三菱制药株式会社 含有人抗il-33单克隆抗体的医药用组合物
KR102735988B1 (ko) * 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
AU2020244106A1 (en) * 2019-03-18 2021-09-30 Alvotech Hf Aqueous formulations of TNF-alpha antibodies in high concentrations
EP3998063A4 (en) * 2019-07-08 2023-03-15 MORESCO Corporation Compositions for preparing microemulsion, microemulsion, method for producing composition and microemulsion, and use of microemulsion
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
JP6667043B1 (ja) * 2019-10-25 2020-03-18 株式会社Moresco マイクロエマルション、及びマイクロエマルションの利用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
EP0486526B2 (en) 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CN1520885A (zh) 1997-10-23 2004-08-18 ������ҩ��ʽ���� 可室温贮存的免疫球蛋白静脉注射制剂
WO2000066160A1 (fr) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
WO2001047554A1 (fr) 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
JP4555436B2 (ja) * 2000-06-29 2010-09-29 富士通株式会社 薄膜樹脂基板への樹脂モールド方法及び高周波モジュール
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
SE0003045D0 (sv) 2000-08-29 2000-08-29 Probi Ab New method
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US20030012786A1 (en) 2001-05-25 2003-01-16 Teoh Leah S. Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
US20040156835A1 (en) 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
CA2448218C (en) 2001-06-21 2012-05-29 Genentech, Inc. Sustained release formulation
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
EP1428537B1 (en) 2001-08-29 2008-11-19 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing antibody
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
GB0202633D0 (en) 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
DE60334678D1 (de) 2002-02-14 2010-12-09 Chugai Pharmaceutical Co Ltd Antikörper enthaltende pharmazeutische lösungen
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
EP1478394B1 (en) 2002-02-27 2008-07-30 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
MY151032A (en) 2002-07-19 2014-03-31 Abbott Lab S A Treatment of tnf? related disorders
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP1592440A4 (en) 2003-02-10 2007-07-11 Elan Pharm Inc IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
RS51041B (sr) 2003-02-28 2010-10-31 Ares Trading S.A. Tečne formulacije tbp-1 proteina koji vezuju faktor tumorske nekroze
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
DE602005004014T2 (de) 2004-03-12 2008-12-11 Intercell Ag Verfahren zur solubilisierung von peptid-mischungen
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
JP2008500995A (ja) 2004-06-01 2008-01-17 アレス トレーディング ソシエテ アノニム タンパク質安定化法
WO2006041970A2 (en) 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008528638A (ja) 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
KR20150055116A (ko) 2005-05-16 2015-05-20 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
WO2006125207A2 (en) 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US20090148406A1 (en) 2005-07-02 2009-06-11 Arecor Limited Stable Aqueous Systems Comprising Proteins
MX2008001068A (es) 2005-07-29 2008-03-19 Amgen Inc Formulacion que inhibe la agregacion de proteina.
EA014513B1 (ru) 2005-08-03 2010-12-30 Иммьюноджен, Инк. Композиция иммуноконъюгата
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
NZ567286A (en) 2005-11-01 2012-03-30 Abbott Biotechnolgy Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
SI1986612T1 (sl) 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080003220A1 (en) 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US7571225B2 (en) 2006-06-29 2009-08-04 Stratavia Corporation Standard operating procedure automation in database administration
JP5535623B2 (ja) 2006-06-30 2014-07-02 アッヴィ バイオテクノロジー リミテッド 自動注射装置
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
KR20090060453A (ko) 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
TW200831129A (en) 2006-10-06 2008-08-01 Amgen Inc Stable formulations
TW200833357A (en) 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
EP2684895A1 (en) 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
AU2008216090A1 (en) 2007-02-16 2008-08-21 Wyeth Protein formulations containing sorbitol
CN103990116A (zh) 2007-04-26 2014-08-20 拜尔健康护理有限责任公司 稳定用于冷冻储藏的重组蛋白液体溶液的方法
BRPI0810710A2 (pt) 2007-05-02 2014-10-21 Hoffmann La Roche Método para estabilização de uma proteína.
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
EP2150537A4 (en) 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
WO2008150490A2 (en) 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2009032128A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2710333A1 (en) 2008-01-03 2009-07-09 Abbott Biotechnology Ltd. Predicting long-term efficacy of a compound in the treatment of psoriasis
WO2009091912A2 (en) 2008-01-15 2009-07-23 Abbott Laboratories Improved mammalian expression vectors and uses thereof
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
EP2271671A2 (en) 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
JP5677411B2 (ja) 2009-04-29 2015-02-25 アッヴィ バイオテクノロジー リミテッド 自動注入機器
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US20120014956A1 (en) 2010-02-02 2012-01-19 Hartmut Kupper Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
RS57543B1 (sr) 2010-06-03 2018-10-31 Abbvie Biotechnology Ltd Primene i kompozicije za lečenje hidradenitis suppurativa (hs)
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤

Also Published As

Publication number Publication date
BR112013011699A2 (pt) 2015-09-29
HUE029457T2 (en) 2017-02-28
AU2011325974A1 (en) 2013-05-09
US20190211093A1 (en) 2019-07-11
HK1189162A1 (zh) 2014-05-30
KR101841527B1 (ko) 2018-03-23
JP5919606B2 (ja) 2016-05-18
SI2637690T1 (sl) 2016-11-30
ZA201406542B (en) 2015-09-30
SMT201600443B (it) 2017-01-10
US20160017030A1 (en) 2016-01-21
CN103458926A (zh) 2013-12-18
DK2637690T3 (da) 2017-01-02
US20220010005A1 (en) 2022-01-13
WO2012065072A2 (en) 2012-05-18
US20140377275A1 (en) 2014-12-25
US20120263731A1 (en) 2012-10-18
LT2637690T (lt) 2016-10-25
JP2016172740A (ja) 2016-09-29
EP2637690B1 (en) 2016-09-21
US8821865B2 (en) 2014-09-02
EP2637690A2 (en) 2013-09-18
SG190069A1 (en) 2013-06-28
ES2601202T3 (es) 2017-02-14
JP6062582B2 (ja) 2017-01-18
TW201641119A (zh) 2016-12-01
TWI606840B (zh) 2017-12-01
CN103458926B (zh) 2016-10-26
CA2815689C (en) 2016-11-22
WO2012065072A3 (en) 2012-07-26
IL226217A (en) 2017-08-31
AU2016202136A1 (en) 2016-04-28
TW201244736A (en) 2012-11-16
SG2014015069A (en) 2014-07-30
CN105854016A (zh) 2016-08-17
AU2011325974B2 (en) 2016-10-27
NZ609469A (en) 2015-02-27
MX344727B (es) 2017-01-05
BR112013011699B1 (pt) 2019-04-24
PL2637690T3 (pl) 2017-03-31
EP2637690A4 (en) 2014-04-30
TWI603739B (zh) 2017-11-01
JP2016128466A (ja) 2016-07-14
IL226217A0 (en) 2013-07-31
RU2013126655A (ru) 2014-12-20
RS55385B1 (sr) 2017-03-31
JP2013543868A (ja) 2013-12-09
KR20130135266A (ko) 2013-12-10
HRP20161753T1 (hr) 2017-02-10
RU2639386C2 (ru) 2017-12-21
RU2015154965A (ru) 2019-01-16
PT2637690T (pt) 2016-12-27
CY1118373T1 (el) 2017-06-28
CA2815689A1 (en) 2012-05-18
MX2013005341A (es) 2013-07-05

Similar Documents

Publication Publication Date Title
ME02506B (me) VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA
HRP20161311T1 (hr) Tekući farmaceutski pripravak
HRP20240485T1 (hr) Pripravci glp-1 i njihova upotreba
ME02859B (me) Formulacija za anti-alfa4beta7 antitelo
HRP20211417T1 (hr) Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka
HRP20191994T1 (hr) Formulacije ketorolaka spremne za uporabu
HRP20241526T1 (hr) Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans
ATE542522T1 (de) Wässrige pharmazeutische formulierung
HRP20191843T1 (hr) Mikobakterijski antigenski pripravak
HRP20200889T1 (hr) Upotreba dugodjelujućih peptida glp-1
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
SI2648520T1 (en) Formulation of dexmedetomidine pre-mixtures
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
HRP20191924T1 (hr) Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
HRP20200102T1 (hr) Formulacije protutijela anti-pdl1
HRP20171092T1 (hr) Stabilna tekuća formulacija amg 416 (velkalcetid)
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
HRP20150819T1 (hr) Derivati metastina i njihova uporaba
HRP20110148T1 (hr) Koncentrirane otopine metotreksata
HRP20201948T1 (hr) Pripravci inhibitora dopa-dekarbokilaze
HRP20191923T1 (hr) Postupci i sastavi za isporuku arilsulfataze a u cns
MX2016000727A (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservante.
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
AR091155A1 (es) Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion
JP2015510882A5 (me)